-imus
Immunosuppressants used outside cancer care.
- Drugs ending in -imus: 14
- Approved somewhere: 5
- With a US drug page: 4
- Stem
- -imus
- Class
- Immunosuppressants used outside cancer care
- Sub-stems
- -rolimus
- Most common targets
- FKBP1A (7), dsDNA antibodies (1), DHODH (1), MTOR (1)
Approved and clinical-stage drugs in ChEMBL whose names ending in -imus or one of its sub-stems, matched by spelling; those with a US drug page link to it.
| Acts on | |||
|---|---|---|---|
| Abetimus sodium | Phase 3 | dsDNA antibodies | dsDNA antibodies inhibitor |
| Gusperimus | Phase 3 | — | — |
| Vidofludimus | Phase 3 | DHODH | Dihydroorotate dehydrogenase inhibitor |
| Abetimus | Phase 2 | — | — |
| Manitimus | Phase 2 | — | — |
| Everolimus | Approved | FKBP1A | FK506-binding protein 1A inhibitor |
| Pimecrolimus | Approved | FKBP1A | FK506-binding protein 1A inhibitor |
| Sirolimus | Approved | FKBP1A | FK506-binding protein 1A inhibitor |
| Temsirolimus | Approved | FKBP1A | FK506-binding protein 1A inhibitor |
| Tacrolimus anhydrous | Approved | FKBP1A | FK506-binding protein 1A inhibitor |
| Ridaforolimus | Phase 3 | MTOR | Serine/threonine-protein kinase mTOR inhibitor |
| Laporolimus | Phase 1 | — | — |
| Olocrolimus | — | FKBP1A | FK506-binding protein 1A inhibitor |
| Zotarolimus | — | FKBP1A | FK506-binding protein 1A inhibitor |
Stem from WHO, The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances (2024); description written by Arca. Drugs, stages, targets and mechanisms from ChEMBL (CC BY-SA 3.0). WHO